Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors

NCT02259725 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT02259725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02259725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Completed
Start date
August 16, 2016
Completion date
August 20, 2020
Enrollment
3 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

gastrinoma, glucagonoma, insulinoma, metastatic gastrointestinal carcinoid tumor, pancreatic polypeptide tumor, pulmonary carcinoid tumor, recurrent gastrointestinal carcinoid tumor, recurrent islet cell carcinoma, somatostatinoma